Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma

Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells

(2014) S.-K. Lee et al.   CLINICAL CANCER RESEARCH

Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system

(2014) Ariz Akhter et al.   JOURNAL OF NEURO-ONCOLOGY

Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors

(2014) By Zhao et al.   Journal for ImmunoTherapy of Cancer

TLR7 Negatively Regulates Dendrite Outgrowth through the Myd88-c-Fos-IL-6 Pathway

(2013) H.-Y. Liu et al.   JOURNAL OF NEUROSCIENCE

Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma

(2012) S. J. Dovedi et al.   BLOOD

Rituximab resistance

(2011) Andrew R. Rezvani et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

TLR1/TLR2 Agonist Induces Tumor Regression by Reciprocal Modulation of Effector and Regulatory T Cells

(2011) Y. Zhang et al.   JOURNAL OF IMMUNOLOGY

Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma

(2010) Thomas J. Smith et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Toll-like receptor agonists in cancer therapy

(2009) Sylvia Adams   Immunotherapy

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

(2009) Svetlana Hamm et al.   Journal of Immunotoxicology

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE